These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 9750920)
1. Dose standardization of botulinum toxin. Van den Bergh PY; Lison DF Adv Neurol; 1998; 78():231-5. PubMed ID: 9750920 [No Abstract] [Full Text] [Related]
2. [Frequency of side effects after botulinum toxin A injections in neurology, rehabilitation and gastroenterology]. Sławek J; Madaliński MH; Maciag-Tymecka I; Duzyński W Pol Merkur Lekarski; 2005 Mar; 18(105):298-302. PubMed ID: 15997637 [TBL] [Abstract][Full Text] [Related]
3. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis]. Wissel J; Entner T Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048 [TBL] [Abstract][Full Text] [Related]
4. Iatrogenic botulism after botulinum toxin type A injections. Coban A; Matur Z; Hanagasi HA; Parman Y Clin Neuropharmacol; 2010 May; 33(3):158-60. PubMed ID: 20150804 [TBL] [Abstract][Full Text] [Related]
5. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Bihari K Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212 [TBL] [Abstract][Full Text] [Related]
7. Management of oromandibular dystonia. Wessberg G Hawaii Dent J; 2003; 34(6):15-6. PubMed ID: 14964082 [No Abstract] [Full Text] [Related]
8. [Botulinum: fashionable drug and effective medication. What the "miracle weapon against crow's feet" can do in addition]. Stiefelhagen P MMW Fortschr Med; 2003 Apr; 145(14):4-6. PubMed ID: 15072266 [No Abstract] [Full Text] [Related]
9. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore. Tan AK Singapore Med J; 1998 Sep; 39(9):403-5. PubMed ID: 9885719 [TBL] [Abstract][Full Text] [Related]
11. [Modern therapy in blepharospasm]. Bereş A Oftalmologia; 2010; 54(1):71-6. PubMed ID: 20540373 [TBL] [Abstract][Full Text] [Related]
12. Inappropriate conclusions from the use of botulinum toxin for the treatment of spasticity. Zakine B; Maisonobe P; Pickett AM Clin Neuropharmacol; 2009; 32(3):171; author reply 172-3. PubMed ID: 19483489 [No Abstract] [Full Text] [Related]
13. Botulinum toxin type A therapy during pregnancy. Bodkin CL; Maurer KB; Wszolek ZK Mov Disord; 2005 Aug; 20(8):1081-2; author reply 1082. PubMed ID: 16007618 [No Abstract] [Full Text] [Related]
14. [Botulinum toxin. Development for therapeutic purposes]. Ceballos-Baumann A Nervenarzt; 2008 Jun; 79 Suppl 1():3-8. PubMed ID: 18927957 [TBL] [Abstract][Full Text] [Related]
15. Botox and Dysport are distinct. Madaliński M Endoscopy; 2000 Jun; 32(6):502-3. PubMed ID: 10863924 [No Abstract] [Full Text] [Related]
16. Supramaximal doses of botulinum toxin for refractory blepharospasm. Levy RL; Berman D; Parikh M; Miller NR Ophthalmology; 2006 Sep; 113(9):1665-8. PubMed ID: 16828511 [TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin A in the management of focal muscle overactivity in children with cerebral palsy. Gibson N; Graham HK; Love S Disabil Rehabil; 2007 Dec; 29(23):1813-22. PubMed ID: 18033606 [TBL] [Abstract][Full Text] [Related]
18. Chemodenervation with botulinum toxin for spasticity and dystonia. The effects on gait. O'Brien CF Adv Neurol; 2001; 87():265-9. PubMed ID: 11347231 [No Abstract] [Full Text] [Related]
19. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens. Slawek J; Bogucki A; Reclawowicz D Neurol Sci; 2005 Apr; 26(1):32-9. PubMed ID: 15877185 [TBL] [Abstract][Full Text] [Related]
20. [A new possibility for focal treatment of spasticity with botulinum neurotoxin. The Danish Society of Neurology]. Jeppesen LL; Dalager T; Meden P Ugeskr Laeger; 2004 Mar; 166(12):1117. PubMed ID: 15067776 [No Abstract] [Full Text] [Related] [Next] [New Search]